Study identifier:D6997L00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
FACT: Anastrozole monotherapy versus maximal oestrogen blockade with anastrozole and fulvestrant combination therapy; an open randomized, comparative, Phase III multicentre study in postmenopausal women with hormone receptor positive breast cancer in first relapse after primary treatment of localized tumor.
Breast Cancer
Phase 3
No
Fulvestrant, Anastrozole
Female
514
Interventional
N/A
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jul 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Anastrozole | Drug: Anastrozole 1 mg oral tablet Other Name: Arimidex Other Name: ZD1033 |
Experimental: 2 Anastrozole + Fulvestrant | Drug: Fulvestrant intramuscular injection 250 mg loading dose (LD) regimen Other Name: Faslodex Other Name: ZD9238 Drug: Anastrozole 1 mg oral tablet Other Name: Arimidex Other Name: ZD1033 |